GenePioneer Biotechnologies Co., Ltd., Nanjing, China. was established in 2015. We headquartered in Jiangsu Life Science and Technology Innovation Park, one of China’s leading national hubs for biomedical innovation. Over the years, we have built more than 2,000 square meters of facilities, including 1,500 square meters of state-of-the-art laboratories, supported by a professional team of over 100 members. Among them are PhD returnees with international training backgrounds and advisors from top medical universities, ensuring that both global perspectives and academic rigor are embedded in our work. Recognized as a National High-Tech Enterprise since 2017, GenePioneer has positioned ourselves as a trusted partner to hospitals, universities, and pharmaceutical companies, offering solutions that seamlessly integrate experimental design, laboratory execution, and advanced bioinformatics.

Our strength lies in combining comprehensive laboratory platforms with robust computational resources to support every stage of pharmaceutical and biomedical research. GenePioneer has developed expertise across multiple dimensions of modern life sciences, from proteomics and chemical biology to data-intensive bioinformatics. By integrating emerging technologies with proven methodologies, we help our partners address complex challenges such as drug target discovery, mechanism validation, and compound optimization. This cross-disciplinary approach ensures that data is not only reliable but also directly translatable into decision-making for new drug development. For pharmaceutical companies, our capabilities mean reduced risk in early-stage projects, greater confidence in preclinical results, and accelerated timelines for moving discoveries toward application.

Our impact can be measured by the scale of its scientific contributions and the breadth of its partnerships:

◆ 500+ proprietary bioinformatics algorithms developed to support diverse research needs.
◆ 45 registered software copyrights and 5 granted patents, reflecting innovation and intellectual property strength.
◆ 700+ collaborations established with hospitals, universities, and pharmaceutical enterprises.
◆ Contributions to 500+ SCI-indexed publications, spanning a wide range of biomedical research areas.

These achievements highlight a consistent commitment to scientific excellence and collaboration. For our pharmaceutical partners, they demonstrate not only the reliability of our platforms but also the credibility of our results in the global scientific community.

leading the future of biomedical discovery and application